Pediatric Formulations of Select Second Line Drugs for Treating Tuberculosis
$299,995N43FY2021AINIH
Via Therapeutics, Llc, Austin TX
Investigators
Abstract
TO DEVELOP LOW-COST, SHELF-STABLE, PATIENT- ADAPTABLE MINI-TABLETS FOR TREATMENT OF TUBERCULOSIS IN PEDIATRICS
View original record on NIH RePORTER →